Aimin Hui currently serves as the Executive President of Fosun Pharma, where he plays a pivotal role in steering the company's global research and development initiatives. His extensive expertise in drug development and clinical trials is exemplified by his leadership in the successful launch of...
Aimin Hui currently serves as the Executive President of Fosun Pharma, where he plays a pivotal role in steering the company's global research and development initiatives. His extensive expertise in drug development and clinical trials is exemplified by his leadership in the successful launch of the mRNA COVID-19 vaccine, BNT162b2, known as FUBITAI in Greater China. This groundbreaking project, initiated in January 2020, involved intricate negotiations and collaborations with BioNTech, showcasing Dr. Hui's adeptness in contract agreements and joint research efforts. Under his guidance, Fosun Pharma not only navigated the complexities of vaccine registration but also executed a comprehensive animal protection study, ensuring the safety and efficacy of the vaccine prior to its launch.
Since joining Fosun Pharma in November 2017, Dr. Hui has progressively taken on greater responsibilities, overseeing the global discovery, development, and registration of the company's diverse R&D pipelines. His role extends to the scientific and medical evaluation of potential license-in opportunities, investments, and mergers and acquisitions within Fosun Pharma and Fosun International Healthcare. Dr. Hui's multifaceted skill set encompasses critical areas such as pharmacovigilance, GCP compliance, and life sciences informatics, positioning him as a key figure in advancing innovative healthcare solutions. His leadership in these domains not only enhances Fosun Pharma's competitive edge but also contributes significantly to the broader landscape of global health, particularly in oncology and infectious diseases. As Chair of the Scientific Committee, Dr. Hui continues to drive strategic initiatives that align with the company's mission to deliver transformative therapies to patients worldwide.
